Skip to main content
Top
Published in: BMC Neurology 1/2022

Open Access 01-12-2022 | Systemic Lupus Erythematosus | Research article

Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus

Authors: Kristoffer A. Zervides, Shorena Janelidze, Jessika Nystedt, Birgitta Gullstrand, Petra Nilsson, Pia C. Sundgren, Anders A. Bengtsson, Oskar Hansson, Andreas Jönsen

Published in: BMC Neurology | Issue 1/2022

Login to get access

Abstract

Background

Neuronal damage in systemic lupus erythematosus (SLE) is common, but the extent and mechanisms are unclear. Neurofilament light (NfL) concentrations rise in plasma and cerebrospinal fluid (CSF) during neuronal damage in various neurological disorders. In this cross-sectional study, plasma and CSF concentrations of NfL were explored as a marker of neuronal damage in SLE.

Methods

Seventy-two consecutive SLE out-patients and 26 healthy controls, all female, aged < 55 years, underwent magnetic resonance imaging (MRI) and neurocognitive testing. NfL concentrations in plasma from all individuals and in CSF from 32 patients were measured with single-molecule array technology. Patients were assessed by a rheumatologist and neurologist to define neuropsychiatric involvement (NPSLE) according to three attribution models: SLICC A, SLICC B and ACR.

Results

Plasma and CSF NfL concentrations correlated strongly (r = 0.72, p < 0.001). Both NPSLE and non-NPSLE patients in all attribution models had higher plasma NfL concentrations compared with healthy controls (log-NfL, pg/ml, mean (SD); healthy controls (0.71 (0.17)); SLICC A model: NPSLE (0.87 (0.13), p = 0.003), non-NPSLE (0.83 (0.18), p = 0.005); SLICC B model: NPSLE (0.87 (0.14), p = 0.001), non-NPSLE (0.83 (0.18), p = 0.008); ACR model: NPSLE (0.86 (0.16), p < 0.001), non-NPSLE (0.81 (0.17), p = 0.044)). Plasma and CSF NfL concentrations did not differ between NPSLE and non-NPSLE patients. Higher plasma NfL concentrations correlated with larger CSF volumes on MRI (r = 0.34, p = 0.005), and was associated with poorer cognitive performance in the domains of simple attention, psychomotor speed and verbal memory. SLICC/ACR-Damage Index ≥1 was independently associated with higher plasma NfL concentrations (β = 0.074, p = 0.038). Higher plasma creatinine concentrations, anti-dsDNA-positivity, low complement C3 levels, or a history of renal involvement were associated with higher plasma NfL concentrations (β = 0.003, p = 0.009; β = 0.072, p = 0.031; β = 0.077, p = 0.027; β = 0.069, p = 0.047, respectively).

Conclusions

Higher plasma NfL concentrations in NPSLE and non-NPSLE patients may indicate a higher degree of neuronal damage in SLE in general, corresponding to cognitive impairment and organ damage development. Furthermore, our results may indicate a higher degree of neuronal breakdown in patients with active SLE, also without overt clinical symptoms. NfL may serve as an indicator of neuronal damage in SLE in further studies.
Literature
1.
go back to reference Ingvarsson RF, Bengtsson AA, Jönsen A. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. Lupus. 2016;25(7):772–80.CrossRef Ingvarsson RF, Bengtsson AA, Jönsen A. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. Lupus. 2016;25(7):772–80.CrossRef
2.
go back to reference Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.CrossRef Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.CrossRef
3.
go back to reference Jönsen A. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology. 2002;41(11):1308–12.CrossRef Jönsen A. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology. 2002;41(11):1308–12.CrossRef
4.
go back to reference Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265–73.CrossRef Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265–73.CrossRef
5.
go back to reference Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Vol. 10, Nature Reviews Neurology: Nature Publishing Group; 2014. p. 579–96. Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Vol. 10, Nature Reviews Neurology: Nature Publishing Group; 2014. p. 579–96.
6.
go back to reference Al RH, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, et al. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Vol. 48, Seminars in arthritis and rheumatism: W.B. Saunders; 2018. p. 240–55. Al RH, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, et al. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Vol. 48, Seminars in arthritis and rheumatism: W.B. Saunders; 2018. p. 240–55.
7.
go back to reference Wiseman SJ, Bastin ME, Hamilton IF, Hunt D, Ritchie SJ, Amft EN, et al. Fatigue and cognitive function in systemic lupus erythematosus: associations with white matter microstructural damage. A diffusion tensor MRI study and meta-analysis. Lupus. 2017;26(6):588–97.CrossRef Wiseman SJ, Bastin ME, Hamilton IF, Hunt D, Ritchie SJ, Amft EN, et al. Fatigue and cognitive function in systemic lupus erythematosus: associations with white matter microstructural damage. A diffusion tensor MRI study and meta-analysis. Lupus. 2017;26(6):588–97.CrossRef
8.
go back to reference Cannerfelt B, Nystedt J, Jönsen A, Lätt J, van Westen D, Lilja A, et al. White matter lesions and brain atrophy in systemic lupus erythematosus patients: correlation to cognitive dysfunction in a cohort of systemic lupus erythematosus patients using different definition models for neuropsychiatric systemic lupus erythematosus. Lupus. 2018;27(7):1140–9.CrossRef Cannerfelt B, Nystedt J, Jönsen A, Lätt J, van Westen D, Lilja A, et al. White matter lesions and brain atrophy in systemic lupus erythematosus patients: correlation to cognitive dysfunction in a cohort of systemic lupus erythematosus patients using different definition models for neuropsychiatric systemic lupus erythematosus. Lupus. 2018;27(7):1140–9.CrossRef
9.
go back to reference Hanly JG, Walsh NMG, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19(5):732–41. Hanly JG, Walsh NMG, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19(5):732–41.
10.
go back to reference Wilhelm AJ, Major AS. Accelerated atherosclerosis in systemic lupus erythematosus: mechanisms and prevention approaches. Vol. 7, International journal of clinical rheumatology: NIH Public Access; 2012. p. 527–39. Wilhelm AJ, Major AS. Accelerated atherosclerosis in systemic lupus erythematosus: mechanisms and prevention approaches. Vol. 7, International journal of clinical rheumatology: NIH Public Access; 2012. p. 527–39.
11.
go back to reference Hakim AM. Small vessel disease. Vol. 10, frontiers in neurology: Frontiers Media S.A; 2019. p. 1020. Hakim AM. Small vessel disease. Vol. 10, frontiers in neurology: Frontiers Media S.A; 2019. p. 1020.
12.
go back to reference Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Vol. 14, nature reviews neurology: Nature Publishing Group; 2018. p. 577–89. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Vol. 14, nature reviews neurology: Nature Publishing Group; 2018. p. 577–89.
13.
go back to reference Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the Neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135–40.CrossRef Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the Neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135–40.CrossRef
14.
go back to reference Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–70.CrossRef Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–70.CrossRef
15.
go back to reference Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Vol. 17, expert review of molecular diagnostics: Taylor and Francis Ltd; 2017. p. 761–70. Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Vol. 17, expert review of molecular diagnostics: Taylor and Francis Ltd; 2017. p. 761–70.
16.
go back to reference Gaetani L, Blennow K, Calabresi P, di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. Vol. 90, journal of neurology, neurosurgery and psychiatry: BMJ Publishing Group; 2019. Gaetani L, Blennow K, Calabresi P, di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. Vol. 90, journal of neurology, neurosurgery and psychiatry: BMJ Publishing Group; 2019.
17.
go back to reference Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48(10):2881–7.CrossRef Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48(10):2881–7.CrossRef
18.
go back to reference Tjensvoll AB, Lauvsnes MB, Zetterberg H, Kvaløy JT, Kvivik I, Maroni SS, et al. Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren’s syndrome. J Neurol. 2021;268(4):1385. Tjensvoll AB, Lauvsnes MB, Zetterberg H, Kvaløy JT, Kvivik I, Maroni SS, et al. Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren’s syndrome. J Neurol. 2021;268(4):1385.
19.
go back to reference Lauvsnes MB, Zetterberg H, Blennow K, Kvaløy JT, Tjensvoll AB, Maroni S, et al. Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. J Neurol. 2021;1:1–11. Lauvsnes MB, Zetterberg H, Blennow K, Kvaløy JT, Tjensvoll AB, Maroni S, et al. Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. J Neurol. 2021;1:1–11.
20.
go back to reference Engel S, Boedecker S, Marczynski P, Bittner S, Steffen F, Weinmann A, et al. Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus. Ther Adv Neurol Disord. 2021;14:175628642110514.CrossRef Engel S, Boedecker S, Marczynski P, Bittner S, Steffen F, Weinmann A, et al. Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus. Ther Adv Neurol Disord. 2021;14:175628642110514.CrossRef
21.
go back to reference Petri M, Orbai AM, Alarcõn GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.CrossRef Petri M, Orbai AM, Alarcõn GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.CrossRef
22.
go back to reference Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, CNS vital signs. Arch Clin Neuropsychol. 2006;21(7):623–43.CrossRef Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, CNS vital signs. Arch Clin Neuropsychol. 2006;21(7):623–43.CrossRef
23.
go back to reference Langensee L, Mårtensson J, Jönsen A, Zervides K, Bengtsson A, Nystedt J, et al. Cognitive performance in systemic lupus erythematosus patients: a cross-sectional and longitudinal study. BMC Rheumatol. 2022;6(1):22.CrossRef Langensee L, Mårtensson J, Jönsen A, Zervides K, Bengtsson A, Nystedt J, et al. Cognitive performance in systemic lupus erythematosus patients: a cross-sectional and longitudinal study. BMC Rheumatol. 2022;6(1):22.CrossRef
24.
go back to reference Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–9.CrossRef Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–9.CrossRef
25.
go back to reference Gladman DD, Ibañez D, Urowltz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91. Gladman DD, Ibañez D, Urowltz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91.
26.
go back to reference Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599–608.CrossRef Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599–608.CrossRef
27.
go back to reference Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57(3):496–500.CrossRef Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57(3):496–500.CrossRef
28.
go back to reference Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsänoja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001;45(5):419–23.CrossRef Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsänoja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001;45(5):419–23.CrossRef
29.
go back to reference Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–49.CrossRef Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–49.CrossRef
30.
go back to reference Sabbadini MG, Manfredi AA, Bozzolo E, Ferrario L, Rugarli C, Scorza R, et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus. 1999;8(1):11–9.CrossRef Sabbadini MG, Manfredi AA, Bozzolo E, Ferrario L, Rugarli C, Scorza R, et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus. 1999;8(1):11–9.CrossRef
31.
go back to reference Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum. 2013;43(3):352–61.CrossRef Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum. 2013;43(3):352–61.CrossRef
32.
go back to reference Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: An update. Vol. 73, annals of the rheumatic diseases: BMJ Publishing Group; 2014. p. 1601–6. Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: An update. Vol. 73, annals of the rheumatic diseases: BMJ Publishing Group; 2014. p. 1601–6.
33.
go back to reference Bengtsson AA, Rönnblom L. Role of interferons in SLE. Vol. 31, best practice and research: clinical rheumatology: Bailliere Tindall Ltd; 2017. p. 415–28. Bengtsson AA, Rönnblom L. Role of interferons in SLE. Vol. 31, best practice and research: clinical rheumatology: Bailliere Tindall Ltd; 2017. p. 415–28.
34.
go back to reference Akamine S, Marutani N, Kanayama D, Gotoh S, Maruyama R, Yanagida K, et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep. 2020;10:1 2020 Nov 23;10(1):1–7.CrossRef Akamine S, Marutani N, Kanayama D, Gotoh S, Maruyama R, Yanagida K, et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep. 2020;10:1 2020 Nov 23;10(1):1–7.CrossRef
35.
go back to reference Nived O, Ingvarsson RF, Jöud A, Linge P, Tydén H, Jönsen A, et al. Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE. Lupus Sci Med. 2020;7(1):e000398.CrossRef Nived O, Ingvarsson RF, Jöud A, Linge P, Tydén H, Jönsen A, et al. Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE. Lupus Sci Med. 2020;7(1):e000398.CrossRef
36.
go back to reference Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, Pettersson S, Elvin K, Öhrvik J, et al. Excess atherosclerosis in systemic lupus erythematosus,-a matter of renal involvement: case control study of 281 SLE patients and 281 individually matched population controls. PLoS One. 2017;12(4):e0174572.CrossRef Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, Pettersson S, Elvin K, Öhrvik J, et al. Excess atherosclerosis in systemic lupus erythematosus,-a matter of renal involvement: case control study of 281 SLE patients and 281 individually matched population controls. PLoS One. 2017;12(4):e0174572.CrossRef
37.
go back to reference Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology. 2017;89(20):2108–14.CrossRef Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology. 2017;89(20):2108–14.CrossRef
38.
go back to reference Kanmogne M, Klein RS. Neuroprotective versus Neuroinflammatory roles of complement: from development to disease. Vol. 44, trends in neurosciences: Elsevier Ltd; 2021. p. 97–109. Kanmogne M, Klein RS. Neuroprotective versus Neuroinflammatory roles of complement: from development to disease. Vol. 44, trends in neurosciences: Elsevier Ltd; 2021. p. 97–109.
39.
go back to reference Donnellan C, Cohen H, Werring DJ. Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review. Rheumatology (Oxford). 2022;61(1):24. Donnellan C, Cohen H, Werring DJ. Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review. Rheumatology (Oxford). 2022;61(1):24.
40.
go back to reference Dobrynina LA, Sh Gadzhieva Z, Shamtieva KV, Kremneva EI, Akhmetzyanov BM, Kalashnikova LA, et al. Microstructural predictors of cognitive impairment in cerebral small vessel disease and the conditions of their formation. Diagnostics. 2020;10(9):720.CrossRef Dobrynina LA, Sh Gadzhieva Z, Shamtieva KV, Kremneva EI, Akhmetzyanov BM, Kalashnikova LA, et al. Microstructural predictors of cognitive impairment in cerebral small vessel disease and the conditions of their formation. Diagnostics. 2020;10(9):720.CrossRef
41.
go back to reference Zervides KA, Janelidze S, Nystedt J, Gullstrand B, Nilsson P, Sundgren PC, et al. PO.1.13 Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus erythematosus. Lupus Sci Med. 2022;9(Suppl 2):A29. Zervides KA, Janelidze S, Nystedt J, Gullstrand B, Nilsson P, Sundgren PC, et al. PO.1.13 Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus erythematosus. Lupus Sci Med. 2022;9(Suppl 2):A29.
42.
go back to reference Zervides K, Janelidze S, Nystedt J, Gullstrand B, Nilsson P, Sundgren P, et al. POS0116 Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus erythematosus. Ann Rheum Dis. 2022;81(Suppl 1):283.CrossRef Zervides K, Janelidze S, Nystedt J, Gullstrand B, Nilsson P, Sundgren P, et al. POS0116 Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus erythematosus. Ann Rheum Dis. 2022;81(Suppl 1):283.CrossRef
Metadata
Title
Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus
Authors
Kristoffer A. Zervides
Shorena Janelidze
Jessika Nystedt
Birgitta Gullstrand
Petra Nilsson
Pia C. Sundgren
Anders A. Bengtsson
Oskar Hansson
Andreas Jönsen
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-022-02998-3

Other articles of this Issue 1/2022

BMC Neurology 1/2022 Go to the issue